Enhanced Portfolio, Ease of Partnership
Created in 2019 by four European-based pharmaceutical companies, Aggrega Pharma is focused on enhancing
our partners portfolios by providing access to the most attractive generic drug product opportunities.
Aggrega Pharma is committed to building a selective, valuable pipeline of generic products by leveraging the vast R&D, clinical and manufacturing experience and capabilities of its members. The shareholders are 4 European companies:
Establish Aggrega Pharma as a premier partner to create a fully integrated pharmaceutical supply chain up to commercialization of drug product.
Invest in Aggrega’s internal drug product portfolio through utilizing Aggrega’s global development, financial strength, and scale in sourcing and manufacturing footprint
Partner using flexible commercial models to co-develop
and co-invest in generic drug products and select 505(b)2 opportunities.
Focus initially on US market and appropriately expand
We are continually looking to expand and increase our finished dose portfolio through collaborative working – a core principle at Aggrega Pharma.
Our partnership combines flexible and innovative business models with collaborative process development to strengthen your products, while reducing your risk.
Our partnership offering is supported by our network of development and commercial manufacturing facilities
at Bluepharma (Portugal) and Rafarm (Greece) as well as our network of finished dose CDMOs in Europe, North America and Asia to meet your global product requirements.
Global Product Launches
Extended and Immediate Release
Oral Solid finished dose development and commercial manufacturing facilities (FDA inspected). Clinical study management expertise through Blueclinical.
Develop, register, supply
and commercialize drug
products globally with focus
on various dosage forms, incl. niche, complex & high potent.
API sourcing, regulatory affairs & distribution.
drug products (ex-US) with
focus on niche, complex
Sterile Injectable and Ophthalmic finished dose development and commercial manufacturing facilities (FDA inspected).
Sérgio Paulo Simões
US General Manager
* Early Development
finishes 2020 with
a growth of over 20%
20 years and prepares
a investment of
200 million euros.
Upsher-Smith And Rafarm announce launch of Moxifloxacin Ophthalmic Solution, USP 0.5%.
Follow Us On:
© 2021 Proudly created with Wix.com
6 Arrow RD, STE 200
Ramsey, New Jersey 07446, USA